ES2174533T3 - Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas. - Google Patents

Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas.

Info

Publication number
ES2174533T3
ES2174533T3 ES98964471T ES98964471T ES2174533T3 ES 2174533 T3 ES2174533 T3 ES 2174533T3 ES 98964471 T ES98964471 T ES 98964471T ES 98964471 T ES98964471 T ES 98964471T ES 2174533 T3 ES2174533 T3 ES 2174533T3
Authority
ES
Spain
Prior art keywords
diol
skin diseases
hydroxy acid
hyperqueratotic
alfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98964471T
Other languages
English (en)
Inventor
Agneta Ganemo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Europe BV
Original Assignee
Yamanouchi Europe BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Europe BV filed Critical Yamanouchi Europe BV
Application granted granted Critical
Publication of ES2174533T3 publication Critical patent/ES2174533T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de una combinación de un diol y un ácido alfa-hidroxi en un vehículo para la preparación de un medicamento para el tratamiento tópico de enfermedades de la piel hiperqueratóticas, caracterizado porque el vehículo tiene propiedades semioclusivas.
ES98964471T 1997-11-25 1998-11-25 Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas. Expired - Lifetime ES2174533T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97203681 1997-11-25

Publications (1)

Publication Number Publication Date
ES2174533T3 true ES2174533T3 (es) 2002-11-01

Family

ID=8228970

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98964471T Expired - Lifetime ES2174533T3 (es) 1997-11-25 1998-11-25 Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas.

Country Status (21)

Country Link
US (1) US6399082B1 (es)
EP (1) EP1032378B1 (es)
CN (1) CN1140266C (es)
AT (1) ATE213939T1 (es)
AU (1) AU754420B2 (es)
BG (1) BG64743B1 (es)
BR (1) BR9815016A (es)
CA (1) CA2310049C (es)
CZ (1) CZ290165B6 (es)
DE (1) DE69804130T2 (es)
DK (1) DK1032378T3 (es)
ES (1) ES2174533T3 (es)
HU (1) HU226065B1 (es)
IS (1) IS2147B (es)
NO (1) NO320100B1 (es)
NZ (1) NZ504458A (es)
PL (1) PL190023B1 (es)
PT (1) PT1032378E (es)
SK (1) SK284505B6 (es)
TR (1) TR200001486T2 (es)
WO (1) WO1999026617A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5778367A (en) * 1995-12-14 1998-07-07 Network Engineering Software, Inc. Automated on-line information service and directory, particularly for the world wide web
JP2002515514A (ja) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの局所送逹のための組成物及び方法
US6410036B1 (en) * 2000-05-04 2002-06-25 E-L Management Corp. Eutectic mixtures in cosmetic compositions
AU2002314847A1 (en) 2001-05-31 2002-12-09 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods comprising alpha-hydroxy acids or derivatives
USRE46558E1 (en) 2005-04-28 2017-09-26 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
US20070189989A1 (en) * 2006-02-16 2007-08-16 Cantwell Maggie Y Cosmetic compositions and methods of making and using the compositions
BRPI0708318A2 (pt) 2006-02-28 2011-05-24 Paloma Pharmaceuticals, Inc. composições e uso de compostos para tratar doenças caracterizadas por proliferação celular e angiogênese
US20110021618A1 (en) * 2008-03-25 2011-01-27 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
ES2336995B1 (es) 2008-10-13 2011-02-09 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica para el cuidado de la piel,cuero cabelludo y uñas.
BRPI1006729B1 (pt) * 2009-04-13 2021-10-05 Sulur Subramaniam Vanangamudi Creme medicinal de ácido fusídico preparado utilizando fusidato de sódio e incorporando um biopolímero e seu processo de preparação
EP2429559A4 (en) * 2009-05-08 2013-08-14 Allmedic Pty Ltd TREATMENT OF PAIN AND / OR INFLAMMATION AS WELL AS TREATMENT AND PREVENTION OF SKIN OR SLICING DISEASES OR TROUBLES
WO2012061630A2 (en) * 2010-11-04 2012-05-10 442 Ventures, Llc Composition and method for treating skin conditions
WO2012112791A1 (en) 2011-02-16 2012-08-23 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
GB2540764A (en) * 2015-07-24 2017-02-01 Fontus Health Ltd Topical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021572A (en) * 1975-07-23 1977-05-03 Scott Eugene J Van Prophylactic and therapeutic treatment of acne vulgaris utilizing lactamides and quaternary ammonium lactates
SE462139B (sv) * 1986-02-04 1990-05-14 Sven Moberg Farmaceutisk komposition, innehaallande propylenglykol och karbamid, foer behandling av bl.a. nagelsvamp och seborroiskt eksem
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
AU658608B2 (en) * 1991-03-25 1995-04-27 Astellas Pharma Europe B.V. Topical preparation containing a suspension of solid lipid particles
WO1994013257A1 (en) * 1992-12-16 1994-06-23 Creative Products Resource Associates, Ltd. Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
US5407958A (en) * 1993-07-30 1995-04-18 Beauticontrol Cosmetics, Inc. Therapeutic skin composition
EP0719133A1 (en) * 1993-09-15 1996-07-03 Unilever Plc Skin care method and composition

Also Published As

Publication number Publication date
HK1034194A1 (en) 2001-10-19
AU754420B2 (en) 2002-11-14
CZ290165B6 (cs) 2002-06-12
ATE213939T1 (de) 2002-03-15
BR9815016A (pt) 2000-10-03
NO320100B1 (no) 2005-10-24
DK1032378T3 (da) 2002-04-15
HU226065B1 (hu) 2008-04-28
PL190023B1 (pl) 2005-10-31
EP1032378A1 (en) 2000-09-06
US6399082B1 (en) 2002-06-04
HUP0100066A2 (hu) 2001-08-28
CZ20001920A3 (cs) 2001-04-11
WO1999026617A1 (en) 1999-06-03
PT1032378E (pt) 2002-07-31
CN1280495A (zh) 2001-01-17
BG64743B1 (bg) 2006-02-28
IS5505A (is) 2000-05-23
AU1965999A (en) 1999-06-15
TR200001486T2 (tr) 2001-07-23
NZ504458A (en) 2002-03-01
SK7432000A3 (en) 2001-05-10
CA2310049C (en) 2008-02-19
NO20002649L (no) 2000-07-24
DE69804130T2 (de) 2002-07-25
SK284505B6 (sk) 2005-05-05
NO20002649D0 (no) 2000-05-24
PL340679A1 (en) 2001-02-12
DE69804130D1 (de) 2002-04-11
CA2310049A1 (en) 1999-06-03
IS2147B (is) 2006-09-15
EP1032378B1 (en) 2002-03-06
BG104470A (en) 2001-03-30
CN1140266C (zh) 2004-03-03
HUP0100066A3 (en) 2006-07-28

Similar Documents

Publication Publication Date Title
ES2174533T3 (es) Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas.
ES2194308T3 (es) Utilizacion de sustancias con una actividad de oxitocina en la preparacion de medicamentos para la curacion de heridas.
PT871473E (pt) Utilizacao de il-10 para curar feridas com cicatrizacao reduzida
AR033342A1 (es) Una composicion otica topica o intranasal para tratar el dolor otico y el uso topico de agonistas de opioides kapa para tratar el dolor otico
BR0309544A (pt) Preparação farmacêutica contendo oxicodona e naloxona
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
PT973497E (pt) Dispositivo transportador farmaceutico adequado para administracao de compostos farmaceuticos a superficies mucosas
GB2335357A (en) Chitosan-gelatin A microparticles
PT1079813E (pt) Dispositivo transportador farmaceutico adequado para entrega de compostos farmaceuticos as superficies mucosas
MX9703694A (es) Tratamiento profilactico y terapeutico de la sensibilizacion e irritacion de la piel.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
ES2141208T3 (es) Utilizacion de una cantidad eficaz de sustancias activas para el tratamiento de pieles mixtas.
ES2167401T3 (es) Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias.
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
ES2181165T3 (es) Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.
DE69633396D1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
WO2003066130A3 (en) Transdermal drug delivery systems
ES2156215T3 (es) Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias.
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
BR0012006A (pt) Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr
WO1998031712A3 (en) Chitosan-conjugates with acidic chelate-complex forming agents
ES2185310T3 (es) Agente antivirico herbario.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1032378

Country of ref document: ES